Sign In
Buy IMNM
$22.80
-0.550 (-2.36%)
At Close: Jul 13, 2026
What This Immunome Sale Means a Day Before a Big FDA Milestone
04:44pm, Sunday, 12'th Jul 2026
An Immunome insider sold 100,000 shares for $2.4 million based on weighted average prices on July 6, 2026 and July 7, 2026. The transaction represents 32% of the insider's total equity holdings in the
Immunome Stock Up 32% in a Month: Here's What You Should Know
11:41am, Friday, 10'th Jul 2026
IMNM jumps 32% in a month. This comes as the FDA accepts varegacestat's NDA for desmoid tumors, with an approval decision expected by April 2027.
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
07:30am, Wednesday, 08'th Jul 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the U.S. Foo
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:02pm, Tuesday, 07'th Jul 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced that the fir
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
02:52pm, Tuesday, 09'th Jun 2026
Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Immunome: Varegacestat Is The Beachhead, But The ADC Engine Is The Thesis
04:44am, Tuesday, 09'th Jun 2026
Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's strong Phase 3 desmoid tumor data and an NDA submission. IMNM's cash position of $582.7M supports operati
4 Biotech Stocks Investors Should Watch in 2026
11:55am, Friday, 05'th Jun 2026
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and soli
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:02pm, Thursday, 04'th Jun 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced
[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today a
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced detailed eff
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
09:00am, Wednesday, 27'th May 2026
[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today ann
Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
04:02pm, Tuesday, 12'th May 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu
